Bactiguard Holding AB
STO:BACTI B

Watchlist Manager
Bactiguard Holding AB Logo
Bactiguard Holding AB
STO:BACTI B
Watchlist
Price: 30.9 SEK 6.19% Market Closed
Market Cap: 959.1m SEK

Bactiguard Holding AB
Investor Relations

Bactiguard Holding AB is a medical device company, which engages in the development and supply of infection protection solutions. The company is headquartered in Stockholm, Stockholm and currently employs 188 full-time employees. The company went IPO on 2014-06-19. Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. The company consists of the noble metals: gold, palladium and silver, which reduces the adhesion of bacteria to the coated surfaces. Its product portfolio includes: BIP Foley Catherer, made from medical grade latex, and BIP Foley Catheter - Silicone, used for drainage and irrigation of the bladder; BIP Endotracheal Tube, for general anesthesia, intensive care, and emergency medicine for airway management and mechanical ventilation; and BIP Central Venous Catherer, made of polyurethane and used to administer drugs and intravenous solutions, monitor pressure and blood sampling. The firm is also present in Portugal, via a distribution agreement with Socime Medical Ltd, and Zambia.

Show more
Loading
BACTI B
OMX Stockholm 30

Earnings Calls

2025 Q3
Jan 16, 2025
Show Transcript
Show Presentation
Show Presentation
Previous
Next
Strong financial performance with growth in digital services and retail
2025 Q3
Jan 16, 2025

Reliance Industries reported robust growth, with Q3 operating revenues up 19.4% year-on-year, totaling INR 33,074 crores. EBITDA increased by 18.8% to INR 16,585 crores, driven by higher data consumption and festive demand. The digital segment thrived, adding 3.3 million subscribers, pushing the total to 482.1 million, while ARPU rose 12% to INR 203.3. Retail revenues reached INR 90,000 crores, up 18.4% quarter-on-quarter, aided by strong festive sales. In O2C, EBITDA grew 2.4% year-on-year at INR 14,400 crores. The outlook remains positive, with ongoing investments expected to support further growth across segments.

Show Full Analysis

Management

Ms. Christine Lind
Chief Executive Officer
No Bio Available
Mr. Patrick Fruergaard Bach
Chief Financial Officer
No Bio Available
Mr. Mikael Sander
Chief Operating Officer
No Bio Available
Ms. Nina Nornholm
Head of Corporate Communication & Investor Relations
No Bio Available
Dr. Nathaniel Bachrach Ph.D.
Interim Head of R&D
No Bio Available

Contacts

Address
STOCKHOLM
Stockholm
Biblioteksgatan 25
Contacts
+4684405880.0
www.bactiguard.se